Multiple Myeloma Hub

HCPS, are you currently re-using anti-CD38 therapy in patients with #MultipleMyeloma who have been previously exposed but were not refractory to it? #mmsm #myeloma #MedeD

🚨NEWS 🚨 The @EMA_News CHMP has issued a positive opinion supporting MRD-negative CR as a potential early endpoint for clinical trials to support conditional approval of treatments in #MultipleMyeloma. This aligns with the recommendation from the @US_FDA Oncologic Drugs Advisory…

🚨 NEWS 🚨 @EU_Commission approves belantamab mafodotin combinations for relapsed/refractory #MultipleMyeloma, with BVd in patients with ≥1 prior therapy and with BPd in those with ≥1 prior therapy including lenalidomide, based on data from the phase III DREAMM-7 and DREAMM-8…

🚨 NEWS 🚨 @EU_Commission has approved isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (Isa-VRd) for the treatment of transplant-eligible newly diagnosed #MultipleMyeloma, based on data from the phase III GMMG-HD7 trial. Learn more:…

🚨 NEWS 🚨 @EU_Commission grants approval to subcutaneous daratumumab monotherapy for the treatment of high-risk smoldering #MultipleMyeloma; based on data from the phase III AQUILA study. This approval represents the first authorized treatment in this indication. Read more:…

Did you know you can filter content on the #MultipleMyeloma Hub website depending on your specific interests – whether that is by multiple myeloma type, therapeutics, trials, or congresses? 👉 loom.ly/lOsGEQ0 #mmsm #MedEd

📝 Preliminary phase I findings presented by Rakesh Popat at #EHA2025 found BCMA/GPRC5D-targeted BsAb JNJ-5322 achieved 100% ORR of 100% at the RP2D in BCMA/GPRC5D-naïve patients with RRMM. More news: multiplemyelomahub.com #MultipleMyeloma #myeloma #MedNews #MedEd

New data 📝 Preliminary phase I findings presented by Rakesh Popat at #EHA2025 show BCMA/GPRC5D-targeted BsAb JNJ-5322 is well tolerated with Grade 3–4 infections reported in 28.6% of patients with RRMM. Learn more: loom.ly/_aDPd-0 #MultipleMyeloma #myeloma #MedNews…

🚨 NEWS 🚨 @US_FDA Oncologic Drugs Advisory Committee votes against the benefit–risk profile of the proposed dosage of belantamab mafodotin for the treatment of R/R #MultipleMyeloma with ≥1 prior line of therapy including lenalidomide. The dosage selected in the BVd combination…

📝 Guidelines for reporting cytogenetic results for MM risk stratification published in @BloodCancerJnl recommend including critical results and use of plain and standardized language.  More news: MultipleMyelomaHub.com #MultipleMyeloma #myeloma #MedNews #MedEd

New publication 📝 Guidelines for testing cytogenetics for MM risk stratification published in @BloodCancerJnl recommend FISH assessment to include TP53 del, 1q gain, 1p del, and primary IGH-r for NDMM. Learn more: loom.ly/FJyCscc #MultipleMyeloma #myeloma #MedNews…

📝 Final analysis of the GMMG-HD7 trial, published in @JCO_ASCO, found that Isa-RVd resulted in prolonged PFS compared with RVd (HR, 0.70; p = 0.0184) in transplant-eligible patients with NDMM.  More news: multiplemyelomahub.com #MultipleMyeloma #myeloma #MedNews #MedEd

New publication 📝 Final analysis of the GMMG-HD7 trial, published in @JCO_ASCO, shows that MRD rates continued to improve with Isa-RVd vs RVd in patients with NDMM post-transplant (66% vs 48%). Learn more: loom.ly/V1nd0N8 #MultipleMyeloma #myeloma #MedNews #MedEd

🚨 NEWS 🚨 The Ministry of Food and Drug Safety of South Korea grants orphan drug designation to equecabtagene autoleucel, for the treatment of R/R #MultipleMyeloma with ≥3 prior lines of therapy, including a PI and an IMiD. loom.ly/R9mqQO4 #myeloma #mmsm #MedNews

📝 Final analysis results of the phase III ALCYONE trial published in @TheLancetOncol found that D-VMP vs VMP was well-tolerated with similar rates of TEAEs (98% vs 97%) in patients with NDMM. More news: MultipleMyelomaHub.com #MultipleMyeloma #myeloma #MedNews #MedEd

HCPs, What is the most significant limitation you have identified when using lenalidomide or pomalidomide for the treatment of patients with #MultipleMyeloma? #mmsm #myeloma #MedEd

New publication 📝 Final analysis of the phase III ALCYONE trial published in @TheLancetOncol show longer median OS with D-VMP vs VMP in transplant-ineligible NDMM (HR, 0.65; p < 0.001). Learn more: loom.ly/SaGiziM #MultipleMyeloma #myeloma #MedNews #MedEd

Ongoing evidence from studies such as AQUILA indicate a potential benefit of early intervention in #MultipleMyeloma. Watch the full video to learn more about the rationale for intervention in high-risk smoldering MM. loom.ly/zGY04dw #mmsm #myeloma #MedEd @myelomaMD…

Catch up with our latest podcast, featuring Shaji Kumar, on the rationale for early intervention in high-risk smoldering #MultipleMyeloma. Listen here: loom.ly/QaeAr4w #mmsm #myeloma #MedEd @myelomaMD @MayoClinic

🚨 NEWS 🚨 @US_FDA grants accelerated approval to linvoseltamab, a bispecific BCMA-directed CD3 T-cell engager, for the treatment of adult patients with RRMM who received ≥4 prior LOT, including a PI, IMiD, and anti-CD38 mAb. Learn more: loom.ly/rns17aE #mmsm #myeloma